protocolSection identificationModule nctId: NCT06324461, orgStudyIdInfo id: GLUMINS, briefTitle: GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery, acronym: GLUMINS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: The University of Hong Kong, class: OTHER, descriptionModule briefSummary: This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 4 days prior to surgery or receive routine care.Semaglutide (Ozempic; Novo Nordisk, Denmark) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery., conditionsModule conditions: Myocardial Injury, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Open-labelled, superiority randomized controlled trial, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 372, type: ESTIMATED, armsInterventionsModule interventions name: Semaglutide 0.25mg subcutaneous injection, outcomesModule primaryOutcomes measure: Proportion of patients with MINS, secondaryOutcomes measure: Proportion of patients with composite of non-fatal MINS, non-fatal stroke or cardiovascular mortality, secondaryOutcomes measure: Proportion of patients with MINS who do not fulfill the 4th universal definition of myocardial infarction, secondaryOutcomes measure: Proportion of patients with myocardial infarction according to the 4th universal definition of myocardial infarction, secondaryOutcomes measure: Proportion of patients with ischemic stroke, secondaryOutcomes measure: Proportion of patients with cardiovascular death, secondaryOutcomes measure: Proportion of patients with all-cause mortality, secondaryOutcomes measure: Mean days alive and out of hospital, secondaryOutcomes measure: Clinically important atrial fibrillation, secondaryOutcomes measure: Clinically significant hypoglycaemia, secondaryOutcomes measure: Mean peak troponin T concentration, secondaryOutcomes measure: Mean area under curve of troponin T concentration, otherOutcomes measure: Proportion of patients with coronary revascularization, otherOutcomes measure: Proportion of patients who require readmission for cardiovascular conditions, otherOutcomes measure: Proportion of patients with non-fatal cardiac arrest, otherOutcomes measure: Proportion of patients who require hospitalization for heart failure, otherOutcomes measure: Proportion of patients who develop pulmonary embolism and/or deep vein thrombosis, otherOutcomes measure: Proportion of patients with International Society on Thrombosis and Haemostasis (ISTH) major bleeding, otherOutcomes measure: Proportion of patients with bleeding independently associated with mortality following noncardiac surgery (BIMS), otherOutcomes measure: Proportion of patients with infection or sepsis, otherOutcomes measure: Proportion of patients with acute renal failure fulfilling Kidney Disease Improving Global Outcomes (KDIGO) criteria, otherOutcomes measure: Proportion of patients with acute renal failure requiring dialysis, otherOutcomes measure: Proportion of patients requiring amputation, otherOutcomes measure: Mean length of stay, otherOutcomes measure: Mean length of intensive care unit stay, otherOutcomes measure: Mean days alive without need for intensive care support, eligibilityModule sex: ALL, minimumAge: 45 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Queen Mary Hospital, city: Hong Kong, state: Hong Kong SAR, country: China, geoPoint lat: 22.39407, lon: 114.13737, hasResults: False